急性白血病异基因造血干细胞移植后的维持治疗研究进展
Research progress on maintenance therapy following allogeneic hematopoietic stem cell transplantation for acute leukemia
杨楚婷 1郑雅龄 1吴明 1黄睿1
作者信息
- 1. 南方医科大学珠江医院血液内科(广州市 510282)
- 折叠
摘要
急性白血病(acute leukemia,AL)是来源于造血干细胞的恶性克隆性疾病,分为急性淋巴细胞白血病(acute lymphoblast-ic leukemia,ALL)和急性髓细胞白血病(acute myeloid leukemia,AML)两大类.异基因造血干细胞移植(allogeneic hema-topoietic stem cell transplantation,allo-HSCT)是AL患者获得长期生存有力的手段,但移植后复发仍然是导致其死亡的主要原因.移植前状态、移植预处理、移植后复发防治均影响移植后的复发.目前,有部分患者移植后维持治疗的研究开展,包括表观遗传学药物、靶向药物、免疫药物等移植后维持治疗.本文主要讨论移植后维持治疗与预后的关系,综述近年来急性白血病allo-HSCT后维持治疗的方法、治疗结局和潜在的不良反应.
Abstract
Acute leukemia(AL)is a malignant clonal disease caused by hematopoietic stem cells.Depending on the cell type involved,AL is classified as acute lymphoblastic leukemia(ALL)or acute myeloid leukemia(AML).Allogeneic hematopoietic stem cell transplantation(allo-HSCT)is an important and effective treatment for patients with AL to achieve long-term survival.However,recurrence after transplantation remains the primary cause of death.Pretransplantation status,transplantation conditioning,and prevention of post-transplantation relapse affects post-transplantation outcomes.This review focuses on post-transplantation maintenance therapy.Several studies on post-trans-plantation maintenance therapy are discussed,including research on post-transplantation maintenance therapy with epigenetic drugs,tar-geted drugs,and immunologic drugs.
关键词
急性白血病/异基因造血干细胞移植/维持治疗/靶向治疗/免疫治疗Key words
acute leukemia(AL)/allogeneic hematopoietic stem cell transplantation(allo-HSCT)/maintenance therapy/targeted ther-apy/immunotherapy引用本文复制引用
出版年
2024
NETL
NSTL
万方数据